查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867597

溶瘤病毒疗法：全球市场份额和排名、总收入和需求预测（2025-2031年）

Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 77 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球溶瘤病毒疗法市场预计在 2024 年达到 1.06 亿美元，预计到 2031 年将达到 2.13 亿美元，2025 年至 2031 年的复合年增长率为 10.4%。

溶瘤病毒疗法是一种创新的癌症治疗方法，它利用基因工程改造的病毒选择性地感染并摧毁癌细胞，同时激活宿主免疫系统，引发全身性抗肿瘤反应。这些病毒能够直接溶解肿瘤细胞并刺激免疫抗原性细胞死亡，使其成为免疫肿瘤学领域的重要治疗方法方向。与化疗和放射线治疗不同，溶瘤病毒治疗方法具有更高的肿瘤选择性、更低的毒性，并且与免疫查核点抑制剂联合使用时，具有强大的协同效应。例如，talimogene laherparepvec (T-VEC) 等产品已获得美国食品药物管理局 (FDA) 的核准，并在治疗黑色素瘤方面展现出良好的疗效，引起了全球製药公司的广泛研发和商业关注。

随着免疫肿瘤学和精准医疗的进步，溶瘤病毒疗法正经历快速发展。透过诸如美国FDA的突破性疗法认定和欧盟的PRIME计画等倡议，世界各地的监管机构都在推动创新，并支持加速临床试验和早期商业化。癌症，尤其是进行性固态肿瘤发生率的不断上升，凸显了对新型作用机制的迫切需求。此外，大型生物製药公司正积极投资于该领域的併购和策略合作，大幅扩展其研发管线。自2023年以来，已有多个溶瘤病毒候选药物进入III期临床试验，显示该领域正朝着工业化规模应用的方向稳步迈进。

儘管前景可期，但溶瘤病毒疗法的研发仍面临许多重大挑战。高效的体内递送和肿瘤特异性标靶化仍是技术难题，尤其是在免疫抑制微环境或病毒清除迅速的患者身上。临床试验耗费大量资源，需要漫长的週期、巨额资金以及病毒学、免疫学和转化医学等跨学科合作。安全性问题依然存在，包括脱靶感染和全身性发炎的风险。此外，该行业缺乏广泛的商业性成功案例，导致投资者情绪谨慎，投资回报也存在不确定性。

下游对创新癌症治疗方法的需求正在迅速增长，溶瘤病毒被认为是下一代免疫疗法联合疗法的关键组成部分。初步数据显示，溶瘤病毒与PD-1/PD-L1阻断等查核点抑制剂合併使用，可能提高包括胶质母细胞瘤、胰臟癌和膀胱癌在内的难治性肿瘤的疗效。这引起了临床医生和患者群体的广泛关注。此外，亚太地区正在崛起为重要的成长引擎，中国、日本和韩国等国家的支持性政策和不断增加的临床试验活动，为未来的区域商业化策略奠定了基础。

本报告旨在按地区/国家、类型和应用对全球溶瘤病毒疗法市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

溶瘤病毒疗法市场规模、估计值和预测均以销售收入为指标，以 2024 年为基准年，并包含 2020 年至 2031 年的历史数据和预测数据。透过定量和定性分析，读者可以製定业务和成长策略，评估竞争格局，分析自身在当前市场中的地位，并就溶瘤病毒疗法做出明智的商业决策。

市场区隔

公司

  • Amgen
  • RIGVIR Group
  • 3s-guojian
  • Shuanghe Pharmaceutical

按类型分類的细分市场

  • 基于HSV的溶瘤病毒
  • 基于腺病毒的溶瘤病毒
  • 基于痘苗病毒的溶瘤病毒
  • 基于水痘口炎病毒的溶瘤病毒
  • 基于新城疫病毒的溶瘤病毒

应用领域

  • 黑色素瘤
  • 摄护腺癌
  • 乳癌
  • 卵巢癌
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Oncolytic Virus Therapy was estimated to be worth US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

Oncolytic Virus Therapy is an innovative cancer treatment approach that employs genetically modified viruses to selectively infect and destroy tumor cells while activating the host's immune system to launch a systemic anti-tumor response. These viruses induce direct oncolysis and stimulate immunogenic cell death, positioning them as a pivotal class in immuno-oncology. Unlike chemotherapy or radiotherapy, this modality offers enhanced tumor selectivity, reduced toxicity, and strong synergistic potential when combined with immune checkpoint inhibitors. Products like Talimogene laherparepvec (T-VEC) have received FDA approval, showing promising efficacy in melanoma and drawing increasing R&D and commercial attention from global pharmaceutical companies.

With breakthroughs in immuno-oncology and the advancement of precision medicine, oncolytic virus therapy is entering a period of rapid growth. Global regulatory bodies are encouraging innovation through frameworks like the FDA's Breakthrough Therapy designation and the EU's PRIME program, facilitating clinical acceleration and early commercialization. The increasing incidence of cancer, particularly advanced solid tumors, underscores the unmet demand for novel mechanisms of action. Furthermore, leading biopharmaceutical companies are actively investing in M&A and strategic partnerships in this space, significantly expanding their pipelines. Since 2023, several oncolytic virus candidates have advanced into Phase III trials, marking a clear shift toward industrial scalability.

Despite promising prospects, several key challenges persist in the development of oncolytic virus therapies. Efficient in vivo delivery and tumor-specific targeting remain technical hurdles, especially in patients with immunosuppressive microenvironments or rapid viral clearance. Clinical trials are resource-intensive, requiring long timelines, significant funding, and multidisciplinary collaboration spanning virology, immunology, and translational medicine. Safety concerns also linger, including risks of off-target infection and systemic inflammation. Additionally, the industry still lacks a broad base of commercially successful precedents, leading to cautious investment sentiment and uncertain return on investment timelines.

The downstream demand for innovative cancer therapies is rapidly rising, with oncolytic viruses increasingly recognized as critical components of next-generation immunotherapy combinations. In difficult-to-treat tumors such as glioblastoma, pancreatic cancer, and bladder cancer, preliminary data indicates enhanced efficacy when combined with checkpoint inhibitors like PD-1/PD-L1. Clinical practitioners and patient communities alike are showing growing interest. Moreover, the Asia-Pacific region is emerging as a significant growth engine, with supportive policies and increasing clinical trial activity in countries like China, Japan, and South Korea, paving the way for future regional commercialization strategies.

This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncolytic Virus Therapy by region & country, by Type, and by Application.

The Oncolytic Virus Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Therapy.

Market Segmentation

By Company

  • Amgen
  • RIGVIR Group
  • 3s-guojian
  • Shuanghe Pharmaceutical

Segment by Type

  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses

Segment by Application

  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oncolytic Virus Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Oncolytic Virus Therapy Product Introduction
  • 1.2 Global Oncolytic Virus Therapy Market Size Forecast (2020-2031)
  • 1.3 Oncolytic Virus Therapy Market Trends & Drivers
    • 1.3.1 Oncolytic Virus Therapy Industry Trends
    • 1.3.2 Oncolytic Virus Therapy Market Drivers & Opportunity
    • 1.3.3 Oncolytic Virus Therapy Market Challenges
    • 1.3.4 Oncolytic Virus Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Oncolytic Virus Therapy Players Revenue Ranking (2024)
  • 2.2 Global Oncolytic Virus Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Oncolytic Virus Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
  • 2.6 Oncolytic Virus Therapy Market Competitive Analysis
    • 2.6.1 Oncolytic Virus Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Oncolytic Virus Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 HSV-based Oncolytic Viruses
    • 3.1.2 Adenoviruses-based Oncolytic Viruses
    • 3.1.3 Vaccinia Virus-based Oncolytic Viruses
    • 3.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
    • 3.1.5 Newcastle Disease Virus-based Oncolytic Viruses
  • 3.2 Global Oncolytic Virus Therapy Sales Value by Type
    • 3.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Oncolytic Virus Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Oncolytic Virus Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Melanoma
    • 4.1.2 Prostate Cancer
    • 4.1.3 Breast Cancer
    • 4.1.4 Ovarian Cancer
    • 4.1.5 Others
  • 4.2 Global Oncolytic Virus Therapy Sales Value by Application
    • 4.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Oncolytic Virus Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Oncolytic Virus Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Oncolytic Virus Therapy Sales Value by Region
    • 5.1.1 Global Oncolytic Virus Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Oncolytic Virus Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Oncolytic Virus Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Oncolytic Virus Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.2.2 North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.5.2 South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.3.2 United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.5.2 China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.9.2 India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Amgen
    • 7.1.1 Amgen Profile
    • 7.1.2 Amgen Main Business
    • 7.1.3 Amgen Oncolytic Virus Therapy Products, Services and Solutions
    • 7.1.4 Amgen Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Amgen Recent Developments
  • 7.2 RIGVIR Group
    • 7.2.1 RIGVIR Group Profile
    • 7.2.2 RIGVIR Group Main Business
    • 7.2.3 RIGVIR Group Oncolytic Virus Therapy Products, Services and Solutions
    • 7.2.4 RIGVIR Group Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 RIGVIR Group Recent Developments
  • 7.3 3s-guojian
    • 7.3.1 3s-guojian Profile
    • 7.3.2 3s-guojian Main Business
    • 7.3.3 3s-guojian Oncolytic Virus Therapy Products, Services and Solutions
    • 7.3.4 3s-guojian Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 3s-guojian Recent Developments
  • 7.4 Shuanghe Pharmaceutical
    • 7.4.1 Shuanghe Pharmaceutical Profile
    • 7.4.2 Shuanghe Pharmaceutical Main Business
    • 7.4.3 Shuanghe Pharmaceutical Oncolytic Virus Therapy Products, Services and Solutions
    • 7.4.4 Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Shuanghe Pharmaceutical Recent Developments

8 Industry Chain Analysis

  • 8.1 Oncolytic Virus Therapy Industrial Chain
  • 8.2 Oncolytic Virus Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Oncolytic Virus Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Oncolytic Virus Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Oncolytic Virus Therapy Market Trends
  • Table 2. Oncolytic Virus Therapy Market Drivers & Opportunity
  • Table 3. Oncolytic Virus Therapy Market Challenges
  • Table 4. Oncolytic Virus Therapy Market Restraints
  • Table 5. Global Oncolytic Virus Therapy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Oncolytic Virus Therapy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Oncolytic Virus Therapy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
  • Table 10. Global Oncolytic Virus Therapy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Oncolytic Virus Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Oncolytic Virus Therapy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Oncolytic Virus Therapy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Oncolytic Virus Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Oncolytic Virus Therapy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Oncolytic Virus Therapy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Oncolytic Virus Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Amgen Basic Information List
  • Table 32. Amgen Description and Business Overview
  • Table 33. Amgen Oncolytic Virus Therapy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Amgen (2020-2025)
  • Table 35. Amgen Recent Developments
  • Table 36. RIGVIR Group Basic Information List
  • Table 37. RIGVIR Group Description and Business Overview
  • Table 38. RIGVIR Group Oncolytic Virus Therapy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Oncolytic Virus Therapy Business of RIGVIR Group (2020-2025)
  • Table 40. RIGVIR Group Recent Developments
  • Table 41. 3s-guojian Basic Information List
  • Table 42. 3s-guojian Description and Business Overview
  • Table 43. 3s-guojian Oncolytic Virus Therapy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Oncolytic Virus Therapy Business of 3s-guojian (2020-2025)
  • Table 45. 3s-guojian Recent Developments
  • Table 46. Shuanghe Pharmaceutical Basic Information List
  • Table 47. Shuanghe Pharmaceutical Description and Business Overview
  • Table 48. Shuanghe Pharmaceutical Oncolytic Virus Therapy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Shuanghe Pharmaceutical (2020-2025)
  • Table 50. Shuanghe Pharmaceutical Recent Developments
  • Table 51. Key Raw Materials Lists
  • Table 52. Raw Materials Key Suppliers Lists
  • Table 53. Oncolytic Virus Therapy Downstream Customers
  • Table 54. Oncolytic Virus Therapy Distributors List
  • Table 55. Research Programs/Design for This Report
  • Table 56. Key Data Information from Secondary Sources
  • Table 57. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Oncolytic Virus Therapy Product Picture
  • Figure 2. Global Oncolytic Virus Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Oncolytic Virus Therapy Report Years Considered
  • Figure 5. Global Oncolytic Virus Therapy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Oncolytic Virus Therapy Revenue in 2024
  • Figure 7. Oncolytic Virus Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. HSV-based Oncolytic Viruses Picture
  • Figure 9. Adenoviruses-based Oncolytic Viruses Picture
  • Figure 10. Vaccinia Virus-based Oncolytic Viruses Picture
  • Figure 11. Vesicular Stomatitis Virus-based Oncolytic Viruses Picture
  • Figure 12. Newcastle Disease Virus-based Oncolytic Viruses Picture
  • Figure 13. Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Oncolytic Virus Therapy Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Product Picture of Melanoma
  • Figure 16. Product Picture of Prostate Cancer
  • Figure 17. Product Picture of Breast Cancer
  • Figure 18. Product Picture of Ovarian Cancer
  • Figure 19. Product Picture of Others
  • Figure 20. Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Oncolytic Virus Therapy Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. North America Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 23. North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Asia Pacific Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
  • Figure 28. South America Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Middle East & Africa Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Key Countries/Regions Oncolytic Virus Therapy Sales Value (%), (2020-2031)
  • Figure 33. United States Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 35. United States Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Europe Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 39. China Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 41. China Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Japan Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Japan Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 45. South Korea Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 47. South Korea Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Southeast Asia Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Southeast Asia Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 51. India Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 53. India Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Oncolytic Virus Therapy Industrial Chain
  • Figure 55. Oncolytic Virus Therapy Manufacturing Cost Structure
  • Figure 56. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 57. Bottom-up and Top-down Approaches for This Report
  • Figure 58. Data Triangulation
  • Figure 59. Key Executives Interviewed